Hourglass Capital’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.96M | Buy |
144,213
+5,804
| +4% | +$315K | 1.66% | 22 |
|
|
2025
Q4 | $6.79M | Buy |
138,409
+7,046
| +5% | +$329K | 1.46% | 29 |
|
|
2025
Q3 | $5.67M | Buy |
131,363
+774
| +0.6% | +$30.2K | 1.27% | 39 |
|
|
2025
Q2 | $5.01M | Buy |
130,589
+12,420
| +11% | +$475K | 1.24% | 38 |
|
|
2025
Q1 | $4.58M | Buy |
+118,169
| New | +$4.33M | 1.2% | 38 |
|
|
2022
Q4 | – | Sell |
-104,085
| Closed | -$3.06M | – | 105 |
|
|
2022
Q3 | $3.06M | Sell |
104,085
-2,170
| -2% | -$82.2K | 1.16% | 38 |
|
|
2022
Q2 | $5.78M | Hold |
106,255
| – | – | 2.05% | 14 |
|
|
2022
Q1 | $5.79M | Buy |
106,255
+26,349
| +33% | +$1.43M | 1.81% | 21 |
|
|
2021
Q4 | $4.41M | Sell |
79,906
-13,040
| -14% | -$678K | 1.48% | 29 |
|
|
2021
Q3 | $4.44M | Sell |
92,946
-10,332
| -10% | -$519K | 1.21% | 37 |
|
|
2021
Q2 | $5.14M | Buy |
103,278
+3,256
| +3% | +$156K | 1.2% | 36 |
|
|
2021
Q1 | $4.46M | Sell |
100,022
-2,248
| -2% | -$102K | 1.13% | 41 |
|
|
2020
Q4 | $4.7M | Sell |
102,270
-5,376
| -5% | -$247K | 1.4% | 33 |
|
|
2020
Q3 | $5.07M | Buy |
107,646
+1,168
| +1% | +$58.5K | 1.71% | 24 |
|
|
2020
Q2 | $5.43M | Buy |
106,478
+1,113
| +1% | +$57.1K | 1.92% | 18 |
|
|
2020
Q1 | $4.99M | Sell |
105,365
-3,113
| -3% | -$166K | 2.12% | 14 |
|
|
2019
Q4 | $6.37M | Sell |
108,478
-4,080
| -4% | -$227K | 1.73% | 24 |
|
|
2019
Q3 | $6M | Sell |
112,558
-9,528
| -8% | -$490K | 1.71% | 29 |
|
|
2019
Q2 | $6.11M | Buy |
122,086
+2,200
| +2% | +$110K | 1.73% | 30 |
|
|
2019
Q1 | $6.26M | Buy |
119,886
+1,568
| +1% | +$78.4K | 1.82% | 28 |
|
|
2018
Q4 | $5.65M | Sell |
118,318
-1,861
| -2% | -$91.7K | 1.78% | 26 |
|
|
2018
Q3 | $6.03M | Sell |
120,179
-11,500
| -9% | -$584K | 1.56% | 27 |
|
|
2018
Q2 | $6.63M | Sell |
131,679
-12,321
| -9% | -$621K | 1.66% | 25 |
|
|
2018
Q1 | $7.03M | Buy |
144,000
+33,896
| +31% | +$1.58M | 1.61% | 29 |
|
|
2017
Q4 | $4.88M | Sell |
110,104
-31,280
| -22% | -$1.45M | 1.11% | 40 |
|
|
2017
Q3 | $7.17M | Buy |
141,384
+1,552
| +1% | +$78.7K | 1.71% | 25 |
|
|
2017
Q2 | $7.54M | Buy |
139,832
+1,572
| +1% | +$83.8K | 1.89% | 20 |
|
|
2017
Q1 | $7.29M | Buy |
138,260
+848
| +0.6% | +$43K | 1.76% | 21 |
|
|
2016
Q4 | $6.62M | Sell |
137,412
-480
| -0.3% | -$23.7K | 1.64% | 24 |
|
|
2016
Q3 | $7.43M | Sell |
137,892
-4,024
| -3% | -$221K | 1.85% | 19 |
|
|
2016
Q2 | $7.69M | Buy |
141,916
+2,656
| +2% | +$140K | 1.9% | 19 |
|
|
2016
Q1 | $7.06M | Buy |
139,260
+2,848
| +2% | +$142K | 1.8% | 20 |
|
|
2015
Q4 | $6.88M | Buy |
136,412
+59,532
| +77% | +$3.03M | 1.78% | 23 |
|
|
2015
Q3 | $3.69M | Buy |
76,880
+1,168
| +2% | +$60.8K | 0.81% | 50 |
|
|
2015
Q2 | $3.94M | Buy |
75,712
+2,312
| +3% | +$130K | 0.62% | 55 |
|
|
2015
Q1 | $4.23M | Buy |
73,400
+7,600
| +12% | +$436K | 0.63% | 54 |
|
|
2014
Q4 | $3.52M | Buy |
+65,800
| New | +$3.68M | 0.63% | 58 |
|
Other funds holding GSK
JEST
Hourglass Capital's GSK Position: Q1 2026 in Review
Hourglass Capital increased its GSK (GSK) stake by 4.2% in Q1 2026, buying an estimated $315K and bringing the position to 144,213 shares worth $7.96M. The position accounts for 1.66% of the portfolio, ranked #22.
Hourglass Capital first reported a position in GSK in Q4 2014 and has held it in 37 quarters since. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Hourglass Capital held 144,213 shares of GSK worth $7.96M as of Q1 2026.
- Hourglass Capital bought 5,804 GSK shares in Q1 2026, an estimated $315K.
- GSK made up 1.66% of Hourglass Capital's portfolio in Q1 2026, its #22 holding.
- Hourglass Capital first reported a position in GSK in Q4 2014 and has held it in 37 quarters since.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Hourglass Capital's 13F filing for Q1 2026, filed 4 May 2026.